Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioFactura Australia
Sydney, New South Wales, Australiabiofactura.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioFactura Australia is a subsidiary of the US-based BioFactura, established to leverage Australia's clinical trial infrastructure and R&D tax incentives for the development of its biosimilar pipeline. The company focuses on high-value biologics, utilizing its proprietary Stable Selection Process (SSP) platform to develop high-yielding, stable cell lines for biosimilar production. Its lead program is BFI-751, a biosimilar to Stelara (ustekinumab), which has undergone Phase 1 clinical evaluation in Australia. BioFactura Australia serves as a strategic hub for the parent company's global clinical development and regulatory strategy.
- Therapeutic areas
- ImmunologyRheumatologyDermatologyGastroenterology
- Modalities
- Monoclonal antibodyBiologicBiosimilar
- Industry
- Biotech
Beyond the preview
Go deeper on BioFactura Australia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioFactura Australia.